WARREN, N.J., Sept. 8, 2020 /PRNewswire/ -- GSK Consumer
Healthcare (LSE/NYSE: GSK) today announced the launch of new
Advil Dual Action, an exclusive formula that combines two of the
most powerful pain fighting ingredients: ibuprofen and
acetaminophen. In February, the Food and Drug Administration (FDA)
approved Advil Dual Action as the first and only over-the-counter
medication that combines ibuprofen and acetaminophen. The widely
used, effective ingredients help to manage pain in two ways:
ibuprofen works through the body, targeting pain at the source,
while acetaminophen blocks pain signals to the brain. The
innovation takes these two powerful pain fighting ingredients and
combines them into one tablet to offer fast, strong pain
relief.
Physical pain is unique to each person who experiences it and it
comes in many forms, yet, the ways we treat and even talk about
pain can be outdated and insufficient. Advil surveyed 1,000 U.S.
adults ages 25 to 65, in partnership with Wakefield Research*, to
understand our relationship with pain: how we experience it, how
frequently, how we treat it and even how we describe it to others.
The results were clear: although 95% of people in America
experience everyday aches and pains, there is no singular,
universal experience surrounding pain.
"With the majority of people who experience body aches and pains
unable to find full relief from just one medication, Advil
recognized that there is so much more potential within the pain
relief category, and it starts with gaining a comprehensive
understanding of how people experience pain," said Albert Shiue, Brand Manager at GSK. "Driven by
GSK's commitment to provide safe and effective pain relief options
and our continued efforts to innovate within the pain category, we
are excited to launch Advil Dual Action, the most innovative OTC
oral pain relief product to hit the market in over 25 years, and
provide people with the tools they need to understand and talk
about their pain."
To explore findings, Advil is launching the new "Next Generation
Pain Report" which offers a deep dive into unique, emerging trends
that point to opportunities for us to understand, address and treat
everyday pain. The report reveals:
- OTC Medications aren't getting the job done: 95% of
people experience everyday aches and pains, but 80% do not always
find complete relief with existing OTC pain treatment options.
- No Pain is the Same: Nearly three-quarters (72%) of U.S.
adults experience what they would consider "multidimensional pain,"
getting different types of body pain at different times. In
addition to the physical sensation of pain, psychological, social
and cultural factors all contribute to an individual's pain
experience.
- Age Is Just a Number: Younger people report experiencing
just as much pain as older generations. One-third (34%) of
Millennials report experiencing pain every day, nearly equal to
that of Gen Xers (36%) and Boomers (35%).
- Over-The-Counter Pain Medications are Misunderstood:
When presented with both true and false statements about the
effects of ibuprofen and acetaminophen, the active ingredients in
the most commonly-used, top recommended pain fighters, 81% answered
at least one question incorrectly about the effects of these
medications.
- A Loss for Words: 62% of U.S. adults feel they aren't
able to effectively communicate the everyday pain they experience –
to their friends, partners and even their doctors.
To help consumers better identify and address their own everyday
aches and pains, Advil is introducing a more modern way to talk
about it. No longer will a rigid sad-to-happy-face scale guide how
we describe our pain. Instead, a modernized scale will expand our
pain lexicon with the common symbols we already use every day:
emojis.
Most adults favor putting a digital-era spin on the traditional
graphic scale that was initially developed for use with children.
More than half (53%) say an emoji chart with multiple types of pain
depicted better represents the pain they feel from a body pain than
a sad-to-happy face scale. With Advil's new pain scale, consumers
will be better able to express their pain, and with Advil Dual
Action, people everywhere have a new option for fast, powerful pain
relief.
Advil Dual Action is now available online and on retail shelves
nationwide.
About Advil Dual Action
Advil Dual Action is an
exclusive pain-fighting formula, combining ibuprofen and
acetaminophen to fight pain in two ways. Ibuprofen is a
nonsteroidal anti-inflammatory (NSAID) that targets pain at the
source, temporarily reducing the production of prostaglandins,
which cause swelling and pain signals. Acetaminophen is a pain
reliever that blocks the transmission of pain signals to the brain.
Advil Dual Action will be available over-the-counter nationwide in
2020.
GSK's commitment to pain relief
We are the world
leader in pain relief. With a portfolio of (systemic and topical)
products to relieve pain, our range brings comfort and ease to
millions. World-leading brands including Advil, Panadol and
Voltaren; and beloved local brands like Excedrin in the US and
Fenbid in China help people manage
their symptoms so they can enjoy life to the fullest.
Important safety information about Advil Dual
Action
Before using the product, consumers should read the
Advil Dual Action drug facts label.
About GSK
We are a science-led global healthcare
company with a special purpose: to help people do more, feel
better, live longer. For further information please visit
www.gsk.com.
About GSK Consumer Healthcare
We are the world's
largest Consumer Healthcare company following our new joint venture
with Pfizer Consumer Healthcare. The new drug application for Advil
Dual Action was approved under the Pfizer name. We develop and
market a portfolio of consumer-preferred and expert-recommended
brands including Sensodyne, parodontax, Poligrip, Advil, Centrum
and Theraflu.
*Methodological Notes
The Advil Survey was conducted
by Wakefield Research (www.wakefieldresearch.com) among 1,000
nationally representative US adults ages 25-65, between
July 16th and July 22nd, 2020, using an email invitation and an
online survey. Quotas have been set to ensure reliable and accurate
representation of the US adult population ages 25-65.
Results of any sample are subject to sampling variation. The
magnitude of the variation is measurable and is affected by the
number of interviews and the level of the percentages expressing
the results. For the interviews conducted in this particular study,
the chances are 95 in 100 that a survey result does not vary, plus
or minus, by more than 3.1 percentage points from the result that
would be obtained if interviews had been conducted with all persons
in the universe represented by the sample.
Media
Inquiries:
|
|
|
|
|
|
|
|
GSK Consumer
Healthcare
|
Caitlin
Kormann
|
+1 617 448
0557
|
(Warren)
|
Edelman
|
Jessica
Moschella
|
+1 201 953
1547
|
(New York
City)
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/gsk-consumer-healthcare-introduces-the-biggest-innovation-in-the-us-over-the-counter-oral-pain-relief-category-in-25-years-new-advil-dual-action-with-acetaminophen-301125691.html
SOURCE GSK Consumer Healthcare